

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=>

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	8.35	1304.85

FILE 'REGISTRY' ENTERED AT 14:37:57 ON 28 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 FEB 2007 HIGHEST RN 923673-01-2
DICTIONARY FILE UPDATES: 27 FEB 2007 HIGHEST RN 923673-01-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> S 173403-65-1/RN

L8 1 173403-65-1/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L8 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):Y
THE ESTIMATED COST FOR THIS REQUEST IS 6.55 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 173403-65-1 REGISTRY
CN DNA, d(P-thio)(A-A-G-G-G-C-T-T-C-T-T-C-C-T-T-A) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Deoxyribonucleic acid, d(P-thio)(A-A-G-G-G-C-T-T-C-T-T-C-C-T-T-A)
FS NUCLEIC ACID SEQUENCE
SQL 16
NA 3 a 4 c 3 g 6 t
NTE

type location description

modified link	a-1	- a-2	P-thio
modified link	a-2	- g-3	P-thio
modified link	g-3	- g-4	P-thio
modified link	g-4	- g-5	P-thio
modified link	g-5	- c-6	P-thio
modified link	c-6	- t-7	P-thio
modified link	t-7	- t-8	P-thio
modified link	t-8	- c-9	P-thio
modified link	c-9	- t-10	P-thio
modified link	t-10	- t-11	P-thio
modified link	t-11	- c-12	P-thio
modified link	c-12	- c-13	P-thio
modified link	c-13	- t-14	P-thio
modified link	t-14	- t-15	P-thio
modified link	t-15	- a-16	P-thio

SEQ 1 aagggttct tcctta

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND

SET COMMAND COMPLETED

=>

=> D HIS

(FILE 'HOME' ENTERED AT 14:14:22 ON 28 FEB 2007)

FILE 'REGISTRY' ENTERED AT 14:15:31 ON 28 FEB 2007

L1 29810 S AGGGCT/SQSN AND SQL<=45
L2 29657 S GAGGTT/SQSN AND SQL<=45
L3 59350 S L1 OR L2

FILE 'USPATFULL' ENTERED AT 14:30:21 ON 28 FEB 2007

L4 4605 S L3
L5 1703 S L4 AND PHARMAC?/SC, SX
L6 15 S L5 AND PY<1997

FILE 'REGISTRY' ENTERED AT 14:35:38 ON 28 FEB 2007

L7 1 S 182442-60-0/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 14:37:57 ON 28 FEB 2007

L8 1 S 173403-65-1/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

INCLS: 435/029.000; 435/032.000; 435/870.000; 435/091.200; 536/023.100;
536/024.300; 536/024.330; 536/024.100; 424/600.000; 424/094.100;
424/278.100; 424/178.100
NCL NCLM: 435/006.000
NCLS: 424/094.100; 424/178.100; 424/278.100; 424/600.000; 435/029.000;
435/032.000; 435/091.200; 435/870.000; 536/023.100; 536/024.100;
536/024.300; 536/024.330
IC [6]
ICM C12Q007-68
ICS C07H021-02; C07H021-04; A01N059-00
IPCI C12Q0007-68 [ICM,6]; C07H0021-02 [ICS,6]; C07H0021-04 [ICS,6];
C07H0021-00 [ICS,6,C*]; A01N0059-00 [ICS,6]
IPCR G01N0033-15 [I,C*]; G01N0033-15 [I,A]; C12N0005-10 [I,C*];
C12N0005-10 [I,A]; C12N0015-09 [I,C*]; C12N0015-09 [I,A];
C12Q0001-68 [I,C*]; C12Q0001-68 [I,A]
EXF 435/6; 435/29; 435/32; 435/870; 536/23.1; 536/29.1; 536/24.3; 536/24.33;
424/500; 424/94.1; 424/278.1; 424/178.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 5811231 19980922
WO 9417208 19940804 <--
CC 3-1 (Biochemical Genetics)
Section cross-reference(s): 1, 4, 9
IT 158858-34-5 158858-35-6 158858-36-7 158858-37-8 158858-38-9
158858-39-0 158858-40-3 158858-41-4 158858-42-5
158858-43-6 158858-44-7 158858-45-8 158858-46-9
158858-47-0 158858-48-1 158858-49-2
(stress gene mRNA-homologous oligonucleotide, compound toxicity
determination in
relation to)

L6 ANSWER 12 OF 15 USPATFULL on STN
AN 96:80257 USPATFULL
TI Phosphorothioate inhibitors of metastatic breast cancer
IN Scholar, Eric M., Omaha, NE, United States
Iversen, Patrick L., Omaha, NE, United States
PA The Board of Regents of The University of Nebraska, Lincoln, NE, United
States (U.S. corporation)
PI [US 5552390 19960903] <--
AI US 1993-164200 19931209 (8)
DT Utility
FS Granted
LN.CNT 763
INCL INCLM: 514/044.000
INCLS: 536/023.100; 536/024.500; 435/240.200; 935/034.000
NCL NCLM: 514/044.000
NCLS: 536/023.100; 536/024.500
IC [6]
ICM A61K048-00
ICS C07H021-04
IPCI A61K0048-00 [ICM,6]; C07H0021-04 [ICS,6]; C07H0021-00 [ICS,6,C*]
IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; C12N0015-11 [I,C*];
C12N0015-11 [I,A]
EXF 514/44; 536/23.1; 536/24.5; 435/6; 435/240.2; 935/34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 5552390 19960903 <--
CC 1-6 (Pharmacology)
Section cross-reference(s): 63
IT 182442-56-4 182442-57-5 182442-58-6 182442-59-7 182442-60-0
182442-61-1 182442-62-2 182442-63-3 182442-64-4
(phosphorothioate inhibitors of metastatic breast cancer)

L6 ANSWER 13 OF 15 USPATFULL on STN
AN 95:71335 USPATFULL
TI Method of controlling fertilization using bombesin or its agonist

IN Spindel, Eliot R., Lake Oswego, OR, United States
Nagalla, Srinivasa R., Portland, OR, United States
Vijayaraghavan, Srinivasan, Beaverton, OR, United States
Archibong, Anthony, Portland, OR, United States
PA Oregon Regional Primate Research Center, Beaverton, OR, United States
(U.S. corporation)
PI US 5439884 19950808 <--
AI US 1992-919731 19920727 (7)
DT Utility
FS Granted
LN.CNT 1021
INCL INCLM: 514/012.000
INCLS: 514/012.000; 514/014.000; 514/015.000
NCL NCLM: 514/012.000
NCLS: 514/013.000; 514/014.000; 514/015.000
IC [6]
ICM A61K038-10
ICS A61K038-17
IPCI A61K0038-10 [ICM,6]; A61K0038-17 [ICS,6]
IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; C07K0007-00 [I,C*];
C07K0007-08 [I,A]; C07K0014-435 [I,C*]; C07K0014-575 [I,A]
EXF 514/14; 514/13; 514/12; 514/15
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 5439884 19950808 <--
CC 2-3 (Mammalian Hormones)
Section cross-reference(s): 1
IT 154339-67-0 154339-68-1 154610-12-5 154610-13-6
154610-14-7 154610-15-8 154610-16-9 154610-18-1
(nucleotide sequence and cloning of)
L6 ANSWER 14 OF 15 USPATFULL on STN
AN 95:60996 USPATFULL
TI Document counting and batching apparatus with counterfeit detection
IN Cargill, N. Allen, Warminster, PA, United States
McInerny, George P., Langhorne, PA, United States
Hughes, Arthur D., Gladwyne, PA, United States
PA Technitrol, Inc., Feasterville, PA, United States (U.S. corporation)
PI US 5430664 19950704 <--
AI US 1993-22145 19930225 (8)
RLI Continuation-in-part of Ser. No. US 1992-913224, filed on 14 Jul 1992,
now abandoned
DT Utility
FS Granted
LN.CNT 1288
INCL INCLM: 364/550.000
INCLS: 194/207.000; 194/213.000; 364/464.010; 377/008.000; 382/135.000
NCL NCLM: 194/207.000
NCLS: 194/213.000; 377/008.000; 382/135.000
IC [6]
ICM G07D007-00
IPCI G07D0007-00 [ICM,6]
IPCR B65H0003-52 [I,C*]; B65H0003-52 [I,A]; G07D0007-00 [I,C*];
G07D0007-04 [I,A]; G07D0007-12 [I,A]; G07D0011-00 [I,C*];
G07D0011-00 [I,A]; G07F0019-00 [I,C*]; G07F0019-00 [I,A]
EXF 194/206; 194/207; 194/213; 364/464.01; 364/550; 377/8; 382/7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 5430664 19950704 <--
CC 7-2 (Enzymes)
Section cross-reference(s): 1, 33
IT 477624-94-5 477624-95-6 477624-96-7 477624-97-8 477624-98-9
477624-99-0 477625-00-6 477625-01-7 477625-02-8 477625-03-9
477625-04-0 477625-05-1 477625-06-2 477625-07-3
477625-08-4 477625-09-5 477625-10-8 477625-11-9 477625-12-0
477625-13-1 477625-14-2 477625-15-3 477625-16-4

477625-17-5	477625-18-6	477625-19-7	477625-20-0	477625-21-1
477625-22-2	477625-23-3	477625-24-4	477625-25-5	477625-26-6
477625-27-7	477625-28-8	477625-29-9	477625-30-2	477625-31-3
477625-32-4	477625-33-5	477625-34-6	477625-35-7	477625-36-8
477625-37-9	477625-38-0	477625-39-1	477625-40-4	
477625-41-5	477625-42-6	477625-43-7	477625-44-8	477625-45-9
477625-46-0	477625-47-1	477625-48-2	477625-49-3	477625-50-6
477625-51-7	477625-52-8	477625-53-9	477625-54-0	
477625-55-1	477625-56-2	477625-57-3	477625-58-4	
477625-59-5	477625-60-8	477625-61-9		
477625-62-0	477625-63-1	477625-64-2	477625-65-3	
477625-66-4	477625-67-5	477625-68-6	477625-69-7	477625-70-0
477625-71-1	477625-72-2	477625-73-3	477625-74-4	477625-75-5
477625-76-6	477625-77-7	477625-78-8	477625-79-9	
477625-80-2	477625-81-3	477625-82-4	477625-83-5	477625-84-6
477625-85-7	477625-86-8	477625-87-9	477625-88-0	477625-89-1
477625-90-4	477625-91-5	477625-92-6	477625-93-7	
477625-94-8	477625-95-9	477625-96-0	477625-97-1	
477625-98-2	477625-99-3	477626-00-9	477626-01-0	
477626-02-1	477626-03-2	477626-04-3	477626-05-4	477626-06-5
477626-07-6	477626-08-7	477626-09-8	477626-10-1	477626-11-2
477626-12-3	477626-13-4	477626-14-5	477626-15-6	477626-16-7
477626-17-8	477626-18-9	477626-19-0	477626-20-3	477626-21-4
477626-22-5	477626-23-6	477626-24-7	477626-25-8	
477626-26-9	477626-27-0	477626-28-1	477626-29-2	
477626-30-5	477626-31-6	477626-32-7	477626-33-8	
477626-34-9	477626-35-0	477626-36-1	477626-37-2	
477626-38-3	477626-39-4	477626-40-7	477626-41-8	477626-42-9
477626-43-0	477626-44-1	477626-45-2	477626-46-3	477626-47-4
477626-48-5	477626-49-6	477626-50-9	477626-51-0	
477626-52-1	477626-53-2	477626-54-3	477626-55-4	
477626-56-5	477626-57-6	477626-58-7	477626-59-8	477626-60-1
477626-61-2	477626-62-3	477626-63-4	477626-64-5	477626-65-6
477626-66-7	477626-67-8	477626-68-9	477626-69-0	
477626-70-3	477626-71-4	477626-72-5	477626-73-6	477626-74-7
477626-75-8	477626-76-9	477626-77-0	477626-78-1	
477626-79-2	477626-80-5	477626-81-6	477626-82-7	
477626-83-8	477626-84-9	477626-85-0	477626-86-1	
477626-87-2	477626-88-3	477626-89-4	477626-90-7	477626-91-8
477626-92-9	477626-93-0	477626-94-1	477626-95-2	477626-96-3
477626-97-4	477626-98-5	477626-99-6	477627-00-2	477627-01-3
477627-02-4	477627-03-5	477627-04-6	477627-05-7	477627-06-8
477627-07-9	477627-08-0	477627-09-1	477627-10-4	477627-11-5
477627-12-6	477627-13-7	477627-14-8	477627-15-9	
477627-16-0	477627-17-1	477627-18-2	477627-19-3	
477627-20-6	477627-21-7	477627-22-8	477627-23-9	
477627-24-0	477627-25-1	477627-26-2	477627-27-3	
477627-28-4	477627-29-5			

(DNAzyme specific for NF- κ B RNA region; enzymic nucleic acid treatment of diseases or conditions related to levels of transcription factor NF- κ B)

IT	477627-30-8	477627-31-9	477627-32-0	477627-33-1	
	477627-34-2	477627-35-3	477627-36-4	477627-37-5	477627-38-6
	477627-39-7	477627-40-0	477627-41-1	477627-42-2	477627-43-3
	477627-44-4	477627-45-5	477627-46-6	477627-47-7	477627-48-8
	477627-49-9	477627-50-2	477627-51-3	477627-52-4	
	477627-53-5	477627-54-6	477627-55-7	477627-56-8	
	477627-57-9	477627-58-0	477627-59-1	477627-60-4	
	477627-61-5	477627-62-6	477627-63-7	477627-64-8	477627-65-9
	477627-66-0	477627-67-1	477627-68-2	477627-69-3	
	477627-70-6	477627-71-7	477627-72-8	477627-73-9	
	477627-74-0	477627-75-1	477627-76-2	477627-77-3	
	477627-78-4	477627-79-5	477627-80-8	477627-81-9	
	477627-82-0	477627-83-1	477627-84-2	477627-85-3	477627-86-4

477627-87-5 477627-88-6 477627-89-7 477627-90-0
 477627-91-1 477627-92-2 477627-93-3 477627-94-4
 477627-95-5 477627-96-6 477627-97-7 477627-98-8 477627-99-9
 477628-00-5 477628-01-6 477628-02-7 477628-03-8
 477628-04-9 477628-05-0 477628-06-1 477628-07-2
 477628-08-3 477628-09-4 477628-10-7 477628-11-8 477628-12-9
 477628-13-0 477628-14-1 477628-15-2 477628-16-3
 477628-17-4 477628-18-5 477628-19-6 477628-20-9
 477628-21-0 477628-22-1 477628-23-2 477628-24-3
 477628-25-4 477628-26-5 477628-27-6 477628-28-7 477628-29-8
 477628-30-1 477628-31-2 477628-32-3
 477628-33-4 477628-34-5 477628-35-6 477628-36-7
 477628-37-8 477628-38-9 477628-39-0 477628-40-3
 477628-41-4 477628-42-5 477628-43-6 477628-44-7
 477628-45-8 477628-46-9 477628-47-0 477628-48-1
 477628-49-2 477628-50-5 477628-51-6 477628-52-7
 477628-53-8 477628-54-9 477628-55-0 477628-56-1
 477628-57-2 477628-58-3 477628-59-4 477628-60-7 477628-61-8
 477628-62-9 477628-63-0 477628-64-1 477628-65-2 477628-66-3
 477628-67-4 477628-68-5 477628-69-6 477628-70-9
 477628-71-0 477628-72-1 477628-73-2 477628-74-3 477628-75-4
 477628-76-5 477628-77-6 477628-78-7 477628-79-8 477628-80-1
 477628-81-2 477628-82-3 477628-83-4 477628-84-5 477628-85-6
 477628-86-7 477628-87-8 477628-88-9 477628-89-0
 477628-90-3 477628-91-4 477628-92-5
 477628-93-6 477628-94-7 477628-95-8 477628-96-9
 477628-97-0 477628-98-1 477628-99-2 477629-00-8
 477629-01-9 477629-02-0 477629-03-1 477629-04-2
 477629-05-3 477629-06-4 477629-07-5 477629-08-6
 477629-09-7 477629-10-0 477629-11-1 477629-12-2
 477629-13-3 477629-14-4 477629-15-5 477629-16-6 477629-17-7
 477629-18-8 477629-19-9 477629-20-2 477629-21-3 477629-22-4
 477629-23-5 477629-24-6 477629-25-7 477629-26-8 477629-27-9
 477629-28-0 477629-29-1 477629-30-4 477629-31-5 477629-32-6
 477629-33-7 477629-34-8 477629-35-9 477629-36-0
 477629-37-1 477629-38-2 477629-39-3 477629-40-6 477629-41-7
 477629-42-8 477629-43-9 477629-44-0 477629-45-1
 477629-46-2 477629-47-3 477629-48-4 477629-49-5
 477629-50-8 477629-51-9 477629-52-0
 477629-53-1 477629-54-2 477629-55-3 477629-56-4
 477629-57-5 477629-58-6 477629-59-7 477629-60-0
 477629-61-1 477629-62-2 477629-63-3 477629-64-4
 477629-65-5

(DNAzyme specific for NF- κ B RNA region; enzymic nucleic acid
 treatment of diseases or conditions related to levels of transcription
 factor NF- κ B)

IT 477629-66-6 477629-67-7 477629-68-8 477629-69-9 477629-70-2
 477629-71-3 477629-72-4 477629-73-5 477629-74-6 477629-75-7
 477629-76-8 477629-77-9 477629-78-0 477629-79-1
 477629-80-4 477629-81-5 477629-82-6 477629-83-7 477629-84-8
 477629-85-9 477629-86-0 477629-87-1
 477629-88-2 477629-89-3 477629-90-6
 477629-91-7 477629-92-8 477629-93-9 477629-94-0
 477629-95-1 477629-96-2 477629-97-3 477629-98-4
 477629-99-5

(DNAzyme specific for NF- κ B RNA region; enzymic nucleic acid
 treatment of diseases or conditions related to levels of transcription
 factor NF- κ B)

L6 ANSWER 15 OF 15 USPATFULL on STN

AN 93:1297 USPATFULL

TI Method for making synthetic oligonucleotides which bind specifically to
 target sites on duplex DNA molecules, by forming a colinear triplex, the
 synthetic oligonucleotides and methods of use

IN Hogan, Michael E., The Woodlands, TX, United States
 Kessler, Donald J., The Woodlands, TX, United States
 PA Baylor College of Medicine, Houston, TX, United States (U.S.
 corporation)
 PI US 5176996 19930105 <--
 AI US 1989-453532 19891222 (7)
 RLI Continuation-in-part of Ser. No. US 1988-287359, filed on 20 Dec 1988,
 now abandoned
 DT Utility
 FS Granted
 LN.CNT 1178
 INCL INCLM: 435/006.000
 INCLS: 435/091.000; 536/024.500; 536/025.100; 436/094.000
 NCL NCLM: 435/006.000
 NCLS: 435/091.300; 435/091.500; 436/094.000; 536/024.500; 536/025.100
 IC [5]
 ICM C12Q001-68
 ICS C12P019-34; C07H015-12; G01N033-00
 IPCI C12Q0001-68 [ICM,5]; C12P0019-34 [ICS,5]; C12P0019-00 [ICS,5,C*];
 C07H0015-12 [ICS,5]; C07H0015-00 [ICS,5,C*]; G01N0033-00 [ICS,5]
 IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [I,C*];
 A61K0048-00 [I,A]; C07H0021-00 [I,C*]; C07H0021-00 [I,A];
 C07H0021-04 [I,A]; C12N0015-11 [I,C*]; C12N0015-11 [I,A];
 C12Q0001-68 [I,C*]; C12Q0001-68 [I,A]; C12Q0001-70 [I,C*];
 C12Q0001-70 [I,A]
 EXF 435/6; 536/91; 536/27; 536/28; 436/94
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 PI US 5176996 19930105 <--
 CC 9-2 (Biochemical Methods)
 Section cross-reference(s): 1, 3
 IT 134010-22-3 134010-33-6 134010-35-8 134010-40-5
 134010-44-9 134010-61-0
 (as target DNA for inhibiting human β globin gene in thalassemia
 and sickle cell anemia, oligonucleotides forming triplexes with target
 DNA for)

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1216.23	1296.50

FILE 'REGISTRY' ENTERED AT 14:35:38 ON 28 FEB 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 27 FEB 2007 HIGHEST RN 923673-01-2
 DICTIONARY FILE UPDATES: 27 FEB 2007 HIGHEST RN 923673-01-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1802PXD

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/Caplus F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/Caplus to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/Caplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/Caplus patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/Caplus accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/Caplus enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/Caplus Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/Caplus updated with revised CAS roles
NEWS	23	JAN 22	CA/Caplus enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	26	FEB 13	CASREACT coverage to be extended
NEWS	27	Feb 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	28	Feb 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	29	Feb 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	30	Feb 26	MEDLINE reloaded with enhancements
NEWS	31	Feb 26	EMBASE enhanced with Clinical Trial Number field
NEWS	32	Feb 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	33	Feb 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	34	Feb 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:14:22 ON 28 FEB 2007

=> file reg	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'REGISTRY' ENTERED AT 14:15:31 ON 28 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 FEB 2007 HIGHEST RN 923673-01-2
DICTIONARY FILE UPDATES: 27 FEB 2007 HIGHEST RN 923673-01-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s AGGGCT/SQSN AND SQL<=45
29810 AGGGCT/SQSN
7926619 SQL<=45
L1 29810 AGGGCT/SQSN AND SQL<=45

=>

=> S GAGGTT/SQSN AND SQL<=45
29657 GAGGTT/SQSN
7926619 SQL<=45
L2 29657 GAGGTT/SQSN AND SQL<=45

=> S L1 OR L2
L3 59350 L1 OR L2

=> FILE USPATFULL	SINCE FILE	TOTAL
COST IN U.S. DOLLARS		

FULL ESTIMATED COST

ENTRY SESSION
79.85 80.27

FILE 'USPATFULL' ENTERED AT 14:30:21 ON 28 FEB 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 27 Feb 2007 (20070227/PD)
FILE LAST UPDATED: 27 Feb 2007 (20070227/ED)
HIGHEST GRANTED PATENT NUMBER: US7185369
HIGHEST APPLICATION PUBLICATION NUMBER: US2007044192
CA INDEXING IS CURRENT THROUGH 26 Feb 2007 (20070226/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 27 Feb 2007 (20070227/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2006

=> S L3

L4 4605 L3

=> L4 AND PHARMAC?/sc,sx

L4 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> S L4 AND PHARMAC?/sc,sx

'SC' IS NOT A VALID FIELD CODE

0 PHARMAC?/SC

132518 PHARMAC?/SX

L5 1703 L4 AND PHARMAC?/SC,SX

=> L5 AND py<1997

L5 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> S L5 AND py<1997

2137539 PY<1997

L6 15 L5 AND PY<1997

=> D BIB AB HITSEQ

'HITSEQ' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'

The following are valid formats:

The default display format is STD.

ABS ----- AB

ALL ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
 RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
 DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
 INCLM, INCLS, NCL, NCLM, NCLS, IC, IPCI,
 IPCI-2, IPCR, EXF, ARTU

ALLG ----- ALL plus PAGE.DRAW

BIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD, RLI,
 PRAI, DT, FS, EXNAM, LREP, CLMN, ECL, DRWN, LN.CNT

BIB.EX ----- BIB for original and latest publication

BIBG ----- BIB plus PAGE.DRAW

BROWSE ----- See "HELP BROWSE" or "HELP DISPLAY BROWSE". BROWSE must
 entered on the same line as DISPLAY, e.g., D BROWSE.

CAS ----- OS, CC, SX, ST, IT

CBIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PRAI, DT, FS

DALL ----- ALL, delimited for post-processing

FP ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI, RLI,
 PRAI, IC, IPCI, IPCI-2, IPCR, INCL, INCLM, INCLS, NCL,
 NCLM, NCLS, EXF, REP, REN, ARTU, EXNAM, LREP,
 CLMN, DRWN, AB
 FP.EX ----- FP for original and latest publication
 FPALL ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,
 RLI, PRAI, IC, IPCI, IPCI-2, IPCR, INCL, INCLM, INCLS, NCL, NCLM,
 NCLS, EXF, REP, REN, ARTU, EXNAM, LREP, CLMN, DRWN, AB,
 PARN, SUMM, DRWD, DETD, CLM
 FPBIB ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,
 RLI, PRAI, REP, REN, EXNAM, LREP, CLM, CLMN, DRWN
 FHITSTR ---- HIT RN, its text modification, its CA index name, and
 its structure diagram
 FPG ----- FP plus PAGE.DRAW
 GI ----- PN and page image numbers
 HIT ----- All fields containing hit terms
 HITRN ----- HIT RN and its text modification
 HITSTR ----- HIT RN, its text modification, its CA index name, and
 its structure diagram
 IABS ----- ABS, indented with text labels
 IALL ----- ALL, indented with text labels
 IALLG ----- IALL plus PAGE.DRAW
 IBIB ----- BIB, indented with text labels
 IBIB.EX ---- IBIB for original and latest publication
 IBIBG ----- IBIB plus PAGE.DRAW
 IMAX ----- MAX, indented with text labels
 IMAX.EX ---- IMAX for original and latest publication
 IND ----- INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, IPCI, IPCI-2, IPCR,
 EXF, ARTU, OS, CC, SX, ST, IT
 IPC.TAB ---- IPC in tabular format
 ISTD ----- STD, indented with text labels
 KWIC ----- All hit terms plus 20 words on either side
 MAX ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
 RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
 DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
 INCLM, INCLS, NCL, NCLM, NCLS, IC, IPCI, IPCI-2,
 IPCR, EXF, ARTU OS, CC, SX, ST, IT
 MAX.EX ---- MAX for original and latest publication
 OCC ----- List of display fields containing hit terms
 SBIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
 DT, FS, LN.CNT
 STD ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
 DT, FS, LN.CNT, INCL, INCLM, INCLS, NCL, NCLM, NCLS,
 IC, IPCI, IPCI-2, IPCR, EXF (STD is the default)
 STD.EX ---- STD for original and latest publication
 TRIAL ----- AN, TI, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC,
 IPCI, IPCI-2, IPCR
 SCAN ----- AN, TI, NCL, NCLM, NCLS, IC, IPCI, IPCI-2, IPCR(random display
 without answer number. SCAN must be entered on the
 same line as DISPLAY, e.g., D SCAN)
 ENTER DISPLAY FORMAT (STD):STD

L6 ANSWER 1 OF 15 USPATFULL on STN
 AN 2006:106874 USPATFULL
 TI Prostate-specific membrane antigen and uses thereof
 IN Israeli, Ron S., Staten Island, NY, UNITED STATES
 Heston, Warren D. W., New York, NY, UNITED STATES
 Fair, William R., New York, NY, UNITED STATES
 PA Sloan-Kettering Institute for Cancer Research, New York, NY, UNITED
 STATES (U.S. corporation)
 PI US 7037647 B1 20060502
 WO 9626272 19960829 <--
 AI US 1996-894583 19960223 (8)

WO 1996-US2424

19960223

19980223 PCT 371 date

RLI Continuation-in-part of Ser. No. US 1995-466381, filed on 6 Jun 1995,
PENDING Continuation-in-part of Ser. No. US 1995-470735, filed on 6 Jun
1995, PENDING Continuation of Ser. No. US 1995-394152, filed on 24 Feb
1995, Pat. No. US 5935818

DT Utility

FS GRANTED

LN.CNT 4974

INCL INCLM: 435/006.000

INCLS: 536/024.100; 536/024.200; 536/024.300; 536/024.310

NCL NCLM: 435/006.000

NCLS: 536/024.100; 536/024.200; 536/024.300; 536/024.310

IC IPCI C12Q0001-68 [I,A]

IPCR A01K0067-027 [I,C*]; A01K0067-027 [I,A]; C12Q0001-68 [I,A];

A61K0039-00 [I,C*]; A61K0039-00 [I,A]; A61K0039-395 [I,C*];

A61K0039-395 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A];

A61K0048-00 [I,C*]; A61K0048-00 [I,A]; A61K0051-00 [I,C*];

A61K0051-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A];

A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07K0014-435 [I,C*];

C07K0014-705 [I,A]; C07K0014-82 [I,C*]; C07K0014-82 [I,A];

C07K0016-18 [I,C*]; C07K0016-32 [I,A]; C12N0005-10 [I,C*];

C12N0005-10 [I,A]; C12N0015-09 [I,C*]; C12N0015-09 [I,A];

C12N0015-12 [I,C*]; C12N0015-12 [I,A]; C12P0021-08 [I,C*];

C12P0021-08 [I,A]; C12Q0001-68 [I,C]

EXF 435/6; 536/24.1; 536/24.2; 536/24.3; 536/24.31

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> D HIS

(FILE 'HOME' ENTERED AT 14:14:22 ON 28 FEB 2007)

FILE 'REGISTRY' ENTERED AT 14:15:31 ON 28 FEB 2007

L1 29810 S AGGGCT/SQSN AND SQL<=45

L2 29657 S GAGGTT/SQSN AND SQL<=45

L3 59350 S L1 OR L2

FILE 'USPATFULL' ENTERED AT 14:30:21 ON 28 FEB 2007

L4 4605 S L3

L5 1703 S L4 AND PHARMAC?/SC,SX

L6 15 S L5 AND PY<1997

=> D 1-15 STD KWIC

L6 ANSWER 1 OF 15 USPATFULL on STN

AN 2006:106874 USPATFULL

TI Prostate-specific membrane antigen and uses thereof

IN Israeli, Ron S., Staten Island, NY, UNITED STATES

Heston, Warren D. W., New York, NY, UNITED STATES

Fair, William R., New York, NY, UNITED STATES

RA Sloan-Kettering Institute for Cancer Research, New York, NY, UNITED
STATES (U.S. corporation)

PI US 7037647 B1 20060502

WO 9626272 19960829

<--

AI US 1996-894583 19960223 (8)

WO 1996-US2424 19960223

19980223 PCT 371 date

RLI Continuation-in-part of Ser. No. US 1995-466381, filed on 6 Jun 1995,
PENDING Continuation-in-part of Ser. No. US 1995-470735, filed on 6 Jun
1995, PENDING Continuation of Ser. No. US 1995-394152, filed on 24 Feb
1995, Pat. No. US 5935818

DT Utility

FS GRANTED

LN.CNT 4974
INCL INCLM: 435/006.000
INCLS: 536/024.100; 536/024.200; 536/024.300; 536/024.310
NCL NCLM: 435/006.000
NCLS: 536/024.100; 536/024.200; 536/024.300; 536/024.310
IC IPCI C12Q0001-68 [I,A]
IPCR A01K0067-027 [I,C*]; A01K0067-027 [I,A]; C12Q0001-68 [I,A];
A61K0039-00 [I,C*]; A61K0039-00 [I,A]; A61K0039-395 [I,C*];
A61K0039-395 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A];
A61K0048-00 [I,C*]; A61K0048-00 [I,A]; A61K0051-00 [I,C*];
A61K0051-00 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A];
A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07K0014-435 [I,C*];
C07K0014-705 [I,A]; C07K0014-82 [I,C*]; C07K0014-82 [I,A];
C07K0016-18 [I,C*]; C07K0016-32 [I,A]; C12N0005-10 [I,C*];
C12N0005-10 [I,A]; C12N0015-09 [I,C*]; C12N0015-09 [I,A];
C12N0015-12 [I,C*]; C12N0015-12 [I,A]; C12P0021-08 [I,C*];
C12P0021-08 [I,A]; C12Q0001-68 [I,C]
EXF 435/6; 536/24.1; 536/24.2; 536/24.3; 536/24.31
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 7037647 B1 20060502
WO 9626272 19960829 <--
CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 1, 7, 13, 14
IT 885504-63-2 885504-64-3 885504-65-4 885504-66-5 885504-67-6
885504-68-7 885504-69-8 885504-70-1 885504-71-2 885504-72-3
885504-73-4 885504-74-5 885504-75-6 885504-76-7 885504-77-8
885504-78-9 885504-79-0 885504-80-3 885504-81-4 885504-82-5
885504-83-6 885504-84-7 885504-87-0 885504-88-1 885504-89-2
885504-90-5 885504-91-6 885504-92-7 885504-93-8 885504-94-9
885504-95-0 885504-96-1 885504-97-2 885504-98-3 885504-99-4
885505-00-0 885505-01-1 885505-02-2 885505-03-3 885505-04-4
885505-05-5 885505-06-6 885505-07-7 885505-08-8 885505-09-9
885505-10-2 885505-11-3 885505-12-4 885505-13-5 885505-14-6
885505-15-7 885505-16-8 885505-17-9 885505-18-0 885505-19-1
885505-20-4 885505-21-5 885505-22-6 885505-23-7 885505-24-8
885505-25-9 885505-26-0 885505-27-1 885505-28-2 885505-29-3
885505-30-6 885505-31-7 885505-32-8 885505-33-9 885505-34-0
885505-35-1 885505-36-2 885505-37-3 885505-38-4
885505-39-5 885505-40-8 885505-41-9 885505-42-0
885505-43-1 885505-44-2 885505-45-3 885505-46-4 885505-47-5
885505-48-6 885505-49-7 885505-50-0 885505-51-1 885505-52-2
885505-53-3 885505-54-4 885505-55-5 885505-56-6 885505-57-7
885505-58-8 885505-59-9 885505-60-2 885505-61-3 885505-62-4
885505-63-5 885505-64-6 885505-65-7 885505-66-8 885505-67-9
885505-68-0 885505-69-1 885505-70-4 885505-71-5 885505-72-6
885505-73-7 885505-74-8
(unclaimed nucleotide sequence; alternatively spliced prostate-specific
membrane antigen and uses thereof in prostate cancer diagnosis and
treatment)
L6 ANSWER 2 OF 15 USPATFULL on STN
AN 2001:136439 USPATFULL
TI Optimized minizymes and miniribozymes and uses thereof
IN McCall, Maxine J., Putney, Australia
Hendry, Philip, Leichhardt, Australia
Lockett, Trevor, Denistone, Australia
PA Commonwealth Scientific and Industrial Research Organization, Parkville,
Australia (non-U.S. corporation)
PI US 6277634 B1 20010821
WO 9640906 19961219 <--
AI US 1998-973568 19980518 (8)
WO 1996-AU343 19960607
19980515 PCT 371 date
19980515 PCT 102(e) date

RLI Continuation of Ser. No. US 1995-574396, filed on 18 Dec 1995, now patented, Pat. No. US 6001648 Continuation-in-part of Ser. No. US 1995-488181, filed on 7 Jun 1995, now patented; Pat. No. US 6004806

DT Utility
FS GRANTED
LN.CNT 2590

INCL INCLM: 435/325.000
INCLS: 435/006.000; 435/091.310; 435/320.100; 435/252.300; 536/023.100; 536/023.200; 536/024.500

NCL NCLM: 435/325.000
NCLS: 435/006.000; 435/091.310; 435/252.300; 435/320.100; 536/023.100; 536/023.200; 536/024.500

IC [7]
ICM C07H021-04
ICS C12N015-85; C12N001-21; C12N015-63
IPCI C07H0021-04 [ICM,7]; C07H0021-00 [ICM,7,C*]; C12N0015-85 [ICS,7]; C12N0001-21 [ICS,7]; C12N0015-63 [ICS,7]
IPCR A61K0038-00 [N,A]; A61K0038-00 [N,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]

EXF 435/6; 435/91.31; 435/172.3; 435/325; 435/252.3; 435/320.1; 435/375; 435/377; 536/23.1; 536/232; 536/24.5; 514/44

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 6277634 B1 20010821
WO 9640906 19961219 <--

CC 3-2 (Biochemical Genetics)
Section cross-reference(s): 1, 7, 14, 63

IT 186272-74-2P
(CAT system minizyme gggttt; oligonucleotide minizymes and mini-ribozymes optimized for RNA hybridization and cleavage for therapeutic and diagnostic uses)

IT 186272-69-5P 186272-77-5P 186272-78-6P 186272-79-7P 186272-80-0P
186272-81-1P 186272-82-2P 186272-83-3P 186272-84-4P 186272-85-5P
186272-86-6P 186272-87-7P 186272-88-8P 186272-89-9P
186272-90-2P 186272-91-3P 186272-92-4P 186272-93-5P
(interleukin-2 system minizyme; oligonucleotide minizymes and mini-ribozymes optimized for RNA hybridization and cleavage for therapeutic and diagnostic uses)

L6 ANSWER 3 OF 15 USPATFULL on STN

AN 2001:43974 USPATFULL

TI Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines

IN Tsarev, Sergei A., Rockville, MD, United States
Emerson, Suzanne U., Rockville, MD, United States
Purcell, Robert H., Boyds, MD, United States

PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)

PI US 6207416 B1 20010327
WO 9610580 19960411 <--

AI US 1997-809523 19970528 (8)
WO 1995-US13102 19951003
19970528 PCT 371 date
19970528 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1994-316765, filed on 3 Oct 1994
Continuation-in-part of Ser. No. US 1992-947263, filed on 18 Sep 1992, now abandoned

DT Utility
FS Granted
LN.CNT 2655

INCL INCLM: 435/069.300
INCLS: 435/320.100; 435/325.000; 435/348.000; 435/005.000; 536/023.720

NCL NCLM: 435/069.300
NCLS: 435/005.000; 435/320.100; 435/325.000; 435/348.000; 536/023.720

IC [7]

ICM C12N015-51
IPCI C12N0015-51 [ICM,7]
IPCR A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0039-00 [N,A];
A61K0039-00 [N,C*]; C07H0021-00 [I,A]; C07H0021-00 [I,C*];
C07K0014-005 [I,C*]; C07K0014-08 [I,A]; C12N0007-00 [I,A];
C12N0007-00 [I,C*]; C12N0015-11 [I,A]; C12N0015-11 [I,C*]
EXF 435/5; 435/320.1; 435/69.3; 435/325; 435/348; 436/513; 436/518; 436/820;
530/350; 536/23.72

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 6207416 B1 20010327
WO 9610580 19960411 <--

CC 15-2 (Immunochemistry)

Section cross-reference(s): 3, 9, 63
IT 331008-61-8 331008-62-9 331008-63-0 331008-64-1 331008-65-2
331008-66-3 331008-67-4 331008-68-5 331008-69-6 331008-70-9
331008-71-0 331008-72-1 331008-73-2 331008-74-3 331008-75-4
331008-76-5 331008-77-6 331008-78-7 331008-79-8 331008-80-1
331008-81-2 331008-82-3 331008-83-4 331008-84-5 331008-85-6
331008-86-7 331008-87-8 331008-88-9 331008-89-0 331008-90-3
331008-91-4 331008-92-5 331008-93-6 331008-94-7 331008-95-8
331008-96-9 331008-97-0 331008-98-1 331008-99-2 331009-00-8
331009-01-9 331009-02-0 331009-03-1 331009-04-2 331009-05-3
331009-06-4 331009-07-5 331009-08-6 331009-09-7
331009-10-0 331009-11-1 331009-12-2 331009-13-3 331009-14-4
331009-15-5 331009-16-6 331009-17-7 331009-18-8 331009-19-9
331009-20-2 331009-21-3 331009-22-4 331009-23-5 331009-24-6
331009-25-7 331009-26-8 331009-27-9 331009-28-0 331009-29-1
331009-30-4 331009-31-5 331009-32-6 331009-33-7 331009-34-8
331009-35-9 331009-36-0 331009-37-1 331009-38-2 331009-39-3
331009-40-6 331009-41-7 331009-42-8 331009-43-9 331009-44-0
331009-45-1 331009-46-2 331009-47-3 331009-48-4 331009-49-5
331009-50-8 331009-51-9 331009-52-0 331009-53-1 331009-54-2
331009-55-3 331009-56-4 331009-57-5 331009-58-6 331009-59-7

(unclaimed nucleotide sequence; recombinant proteins of a pakistani strain of hepatitis E virus and their use in diagnostic methods and vaccines)

L6 ANSWER 4 OF 15 USPATFULL on STN

AN 2000:157555 USPATFULL

TI Modified hemoglobin-like compounds and methods of purifying same

IN Trimble, Stephen P., Boulder, CO, United States

Mathews, Antony J., Boulder, CO, United States

Kerwin, Bruce A., Lafayette, CO, United States

Marquardt, David A., Longmont, CO, United States

Anthony-Cahill, Spencer, Bellingham, WA, United States

Epp, Janet K., Boulder, CO, United States

Madril, Dominic G., Loveland, CO, United States

Anderson, David C., San Bruno, CA, United States

PA Baxter Biotech Technology Sarl, Neuchatel, Switzerland (non-U.S. corporation)

PI US 6150506 20001121

WO 9640920 19961219 <--

AI US 1998-973629 19980824 (8)

WO 1996-US10420 19960606

19980824 PCT 371 date

19980824 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1995-487431, filed on 7 Jun 1995, now patented, Pat. No. US 5844090 which is a continuation-in-part of Ser. No. US 240712

DT Utility

FS Granted

LN.CNT 2238

INCL INCLM: 530/385.000

INCLS: 530/361.000; 435/069.100

NCL NCLM: 530/385.000
 NCLS: 435/069.100; 530/361.000
 IC [7]
 ICM C07K014-805
 ICS A61K035-14
 IPCI C07K0014-805 [ICM,7]; C07K0014-795 [ICM,7,C*]; A61K0035-14 [ICS,7]
 IPCR A61K0038-00 [N,A]; A61K0038-00 [N,C*]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]; C07K0014-795 [I,C*]; C07K0014-805 [I,A]; C12N0015-81 [I,A]; C12N0015-81 [I,C*]
 EXF 435/69.7; 435/69.1; 435/69.6; 435/440; 435/252.3; 435/254.11; 435/71.1; 435/320.1; 435/325; 530/385; 530/829; 530/350; 530/380; 530/402; 530/408; 530/412; 530/416; 530/361; 536/23.5; 536/23.4; 514/832; 252/182.11; 252/183.11
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 PI US 6150506 20001121
 WO 9640920 19961219 <--
 CC 6-3 (General Biochemistry)
 Section cross-reference(s): 9, 63
 IT 116851-28-6 198043-49-1, 2: PN: US6150506 SEQID: 5 unclaimed DNA
 198043-50-4, 3: PN: US6150506 SEQID: 6 unclaimed DNA 198043-51-5, 4: PN: US6150506 SEQID: 7 unclaimed DNA 198043-59-3, GenBank I64787
 243772-51-2, GenBank AR063150 243772-52-3, GenBank AR063151
 307360-87-8, 1: PN: US6150506 SEQID: 4 unclaimed DNA 307360-88-9, 5: PN: US6150506 SEQID: 8 unclaimed DNA 307360-89-0, 6: PN: US6150506 SEQID: 9 unclaimed DNA 307360-90-3, 7: PN: US6150506 SEQID: 10 unclaimed DNA 307360-91-4, 8: PN: US6150506 SEQID: 11 unclaimed DNA 307360-92-5, 9: PN: US6150506 SEQID: 12 unclaimed DNA 307360-93-6
 307360-94-7 307360-95-8 307360-96-9 307360-97-0
 307360-98-1 307360-99-2 307361-00-8 307361-01-9
 307361-02-0 307361-03-1 307361-04-2 307361-05-3
 (unclaimed nucleotide sequence; modified Hb-like compds. and methods of purifying same)
 L6 ANSWER 5 OF 15 USPATFULL on STN
 AN 2000:117501 USPATFULL
 TI Systematic evolution of ligands by exponential enrichment: tissue select
 IN Jensen, Kirk B, New York, NY, United States
 Chen, Hang, San Francisco, CA, United States
 Morris, Kevin N., Goldegg, Austria
 Stephens, Andrew, Boulder, CO, United States
 Gold, Larry, Boulder, CO, United States
 PA NeXstar Pharmaceuticals, Inc., Boulder, CO, United States (U.S. corporation)
 PI US 6114120 20000905
 WO 9634875 19961107 <--
 AI US 1997-945909 19971028 (8)
 WO 1996-US6060 19960501
 19971028 PCT 371 date
 19971028 PCT 102(e) date
 RLI Continuation-in-part of Ser. No. US 1995-434425, filed on 3 May 1995, now patented, Pat. No. US 5789157 And a continuation-in-part of Ser. No. US 1995-437667, filed on 3 May 1995, now patented, Pat. No. US 5864026 And a continuation-in-part of Ser. No. US 1995-434001, filed on 3 May 1995, now patented, Pat. No. US 5712375 And a continuation-in-part of Ser. No. US 1995-433585, filed on 3 May 1995, now patented, Pat. No. US 5763566
 DT Utility
 FS Granted
 LN.CNT 3551
 INCL INCLM: 435/006.000
 INCLS: 435/091.200; 536/022.100; 536/024.300; 536/025.400
 NCL NCLM: 435/006.000
 NCLS: 435/091.200; 536/022.100; 536/024.300; 536/025.400

IC [7]
ICM C07H021-02
ICS C07H021-04; C12P019-34; C12Q001-68
IPCI C07H0021-02 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*];
C12P0019-34 [ICS,7]; C12P0019-00 [ICS,7,C*]; C12Q0001-68 [ICS,7]
IPCR C12N0015-10 [I,A]; C12N0015-10 [I,C*]; C12Q0001-68 [I,A];
C12Q0001-68 [I,C*]

EXF 435/6; 435/91.2; 536/22.1; 536/23.1; 536/25.4; 536/24.3; 935/77.78

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 6114120 20000905

WO 9634875 19961107

<--

CC 3-1 (Biochemical Genetics)

Section cross-reference(s): 1, 9

IT 290848-05-4 290848-06-5 290848-07-6 290848-08-7 290848-09-8
290848-10-1 290848-11-2 290848-12-3 290848-13-4 290848-14-5
290848-15-6 290848-16-7 290848-17-8 290848-18-9 290848-19-0
290848-20-3 290848-21-4 290848-22-5 290848-23-6 290848-24-7
290848-25-8 290848-26-9 290848-27-0 290848-28-1 290848-29-2
290848-30-5 290848-31-6 290848-32-7 290848-33-8
290848-34-9 290848-35-0 290848-36-1 290848-37-2 290848-38-3
290848-39-4 290848-40-7 290848-41-8 290848-42-9 290848-43-0
290848-44-1 290848-45-2 290848-46-3 290848-47-4 290848-48-5
290848-49-6 290848-50-9 290848-51-0 290848-52-1 290848-53-2
290848-54-3 290848-55-4 290848-56-5 290848-57-6 290848-58-7
290848-59-8 290848-60-1 290848-61-2 290848-62-3 290848-63-4
290848-64-5 290848-66-7 290848-67-8 290848-68-9 290848-69-0
290848-70-3 290848-71-4 290848-72-5 290848-73-6 290848-74-7
290848-75-8 290848-76-9 290848-77-0 290848-78-1
290848-79-2 290848-80-5 290848-81-6 290848-82-7 290848-83-8
290848-84-9 290848-85-0 290848-86-1 290848-87-2 290848-88-3
290848-89-4 290848-90-7 290848-91-8 290848-92-9 290848-93-0
290848-94-1 290848-95-2 290848-96-3 290848-97-4 290848-98-5
290848-99-6 290849-00-2 290849-01-3 290849-02-4 290849-03-5
290849-04-6 290849-05-7 290849-06-8 290849-07-9 290849-08-0
290849-09-1 290849-10-4 290849-11-5 290849-12-6 290849-13-7
290849-14-8 290849-15-9 290849-16-0 290849-17-1 290849-18-2
290849-19-3 290849-20-6 290849-21-7 290849-22-8 290849-23-9
290849-24-0 290849-25-1 290849-26-2 290849-27-3 290849-28-4
290849-29-5 290849-30-8 290849-31-9 290849-32-0 290849-33-1
290849-34-2 290849-35-3 290849-36-4 290849-37-5 290849-38-6
290849-39-7 290849-40-0 290849-41-1 290849-42-2 290849-43-3
290849-44-4 290849-45-5 290849-46-6 290849-47-7 290849-48-8
290849-49-9 290849-50-2 290849-51-3 290849-52-4
290849-53-5 290849-54-6 290849-55-7 290849-56-8 290849-57-9
290849-58-0 290849-59-1 290849-60-4 290849-61-5 290872-96-7

(unclaimed sequence; selection of nucleic acid ligands for specific tissues by systematic evolution of ligands by exponential enrichment, tissue SELEX)

(*) L6 ANSWER 6 OF 15 USPATFULL on STN
AN 2000:98219 USPATFULL
TI Retrovirus vectors derived from avian sarcoma leukosis viruses
permitting transfer of genes into mammalian cells
IN Barsov, Eugene, Frederick, MD, United States
Hughes, Stephen H., Smithsburg, MD, United States
PA The United States of America as represented by the Department of Health
and Human Services, Washington, DC, United States (U.S. government)
PI US 6096534 20000801
WO 9637625 19961128 <--
AI US 1997-875509 19971128 (8)
WO 1996-US7370 19960522
19971128 PCT 371 date
19971128 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1995-445462, filed on 22 May 1995,

now abandoned
 DT Utility
 FS Granted
 LN.CNT 1608
 INCL INCLM: 435/320.100
 INCLS: 435/235.100; 435/325.000
 NCL NCLM: 435/320.100
 NCLS: 435/235.100; 435/325.000
 IC [7]
 ICM C12N015-00
 ICS C12N007-00; C12N005-10
 IPCI C12N0015-00 [ICM,7]; C12N0007-00 [ICS,7]; C12N0005-10 [ICS,7]
 IPCR A61K0048-00 [N,A]; A61K0048-00 [N,C*]; C07K0014-005 [I,C*];
 C07K0014-15 [I,A]; C12N0015-867 [I,A]; C12N0015-867 [I,C*]
 EXF 435/320.1; 435/235.1; 435/325; 424/93.1; 424/93.21; 514/44
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 PI US 6096534 20000801
 WO 9637625 19961128 <--
 CC 3-5 (Biochemical Genetics)
 Section cross-reference(s): 1, 10, 13, 15
 IT 287215-54-7, 1: PN: US6096534 SEQID: 1 unclaimed DNA 287215-55-8, 2:
 PN: US6096534 SEQID: 2 unclaimed DNA 287215-56-9, 3: PN:
 US6096534 SEQID: 3 unclaimed DNA 287215-57-0, 4: PN: US6096534 SEQID: 4
 unclaimed DNA 287215-58-1, 5: PN: US6096534 SEQID: 5 unclaimed DNA
 287215-59-2, 6: PN: US6096534 SEQID: 6 unclaimed DNA
 (unclaimed nucleotide sequence; retrovirus vectors derived from avian
 sarcoma leukosis viruses permitting transfer of genes into mammalian
 cells)
 L6 ANSWER 7 OF 15 USPATFULL on STN
 AN 2000:92071 USPATFULL
 TI Nematode-extracted serine protease inhibitors and anticoagulant proteins
 IN Vlasuk, George Phillip, Carlsbad, CA, United States
 Stanssens, Patrick Eric Hugo, St-Martens-Latem, Belgium
 Messens, Joris Hilda Lieven, Dilbeek, Belgium
 Lauwereys, Marc Josef, Haaltert, Belgium
 LaRoche, Yves Rene, Brussels, Belgium
 Jespers, Laurent Stephane, Tervuren, Belgium
 Gansemans, Yannick Georges Jozef, Ichtegem, Belgium
 Moyle, Matthew, Boulder, CO, United States
 Bergum, Peter W., San Diego, CA, United States
 PA Corvas International, Inc., San Diego, CA, United States (U.S.
 corporation)
 PI US 6090916 20000718
 WO 9612021 19960425 <--
 AI US 1997-809455 19971124 (8)
 WO 1995-US13231 19951017
 19971124 PCT 371 date
 19971124 PCT 102(e) date
 RLI Continuation-in-part of Ser. No. US 1995-461965, filed on 5 Jun 1995,
 now patented, Pat. No. US 5872098 And a continuation-in-part of Ser. No.
 US 1995-465380, filed on 5 Jun 1995, now patented, Pat. No. US 5863894
 And a continuation-in-part of Ser. No. US 1995-486397, filed on 5 Jun
 1995, now patented, Pat. No. US 5866542 And a continuation-in-part of
 Ser. No. US 1995-486399, filed on 5 Jun 1995, now patented, Pat. No. US
 5866543 which is a continuation-in-part of Ser. No. US 1994-326110,
 filed on 15 Oct 1994, now patented, Pat. No. US 5945275
 DT Utility
 FS Granted
 LN.CNT 7802
 INCL INCLM: 530/350.000
 NCL NCLM: 530/350.000
 IC [7]
 ICM C07K001-00

IPCI C07K0001-00 [ICM,7]
IPCR A61K0038-00 [N,A]; A61K0038-00 [N,C*]; C07K0014-81 [I,A];
C07K0014-81 [I,C*]

EXF 530/350

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 6090916 20000718

WO 9612021 19960425

<--

CC 7-3 (Enzymes)

Section cross-reference(s): 1

IT 113873-10-2 139528-83-9 178097-46-6 178097-48-8 178097-52-4
178097-53-5 178097-54-6 178154-65-9 178154-66-0 178154-67-1
178154-70-6 178154-71-7 178154-72-8 178154-73-9 178154-74-0
178154-76-2 178154-78-4 178154-80-8 178154-82-0 178154-84-2
178154-88-6 178154-90-0 181973-00-2 181976-67-0 243920-40-3, 1:
PN: US6090916 SEQID: 1 unclaimed DNA 243920-41-4, 2: PN: US6090916
SEQID: 2 unclaimed DNA 243920-43-6 244060-87-5, PN: US5955294 SEQID:
88 unclaimed DNA 244060-88-6, PN: US5955294 SEQID: 89 unclaimed DNA
244060-89-7, PN: US5955294 SEQID: 90 unclaimed DNA 244060-90-0, PN:
US5955294 SEQID: 91 unclaimed DNA 244060-91-1, PN: US5955294 SEQID: 94
unclaimed DNA 244060-92-2, PN: US5955294 SEQID: 95 unclaimed DNA
244060-93-3, PN: US5955294 SEQID: 99 unclaimed DNA 244060-94-4, PN:
US5955294 SEQID: 100 unclaimed DNA 244060-95-5, PN: US5955294 SEQID:
102 unclaimed DNA 244060-96-6, PN: US5955294 SEQID: 103 unclaimed DNA
244060-97-7, PN: US5955294 SEQID: 104 unclaimed DNA 244060-98-8, PN:
US5955294 SEQID: 105 unclaimed DNA 244060-99-9, PN: US5955294 SEQID:
107 unclaimed DNA 244061-00-5, PN: US5955294 SEQID: 108 unclaimed DNA
244061-06-1, PN: US5955294 SEQID: 111 unclaimed DNA 244061-07-2, PN:
US5955294 SEQID: 112 unclaimed DNA 244061-08-3, PN: US5955294 SEQID:
113 unclaimed DNA 244061-09-4, PN: US5955294 SEQID: 114 unclaimed DNA
244061-10-7, PN: US5955294 SEQID: 115 unclaimed DNA 244061-11-8, PN:
US5955294 SEQID: 117 unclaimed DNA 244061-14-1, PN: US5955294 SEQID:
120 unclaimed DNA 244061-15-2, PN: US5955294 SEQID: 121
unclaimed DNA 244061-16-3, PN: US5955294 SEQID: 122 unclaimed DNA
244061-17-4, PN: US5955294 SEQID: 123 unclaimed DNA 244061-18-5, PN:
US5955294 SEQID: 124 unclaimed DNA 244061-19-6, PN: US5955294 SEQID:
125 unclaimed DNA 244061-20-9, PN: US5955294 SEQID: 126 unclaimed DNA
244061-21-0, PN: US5955294 SEQID: 127 unclaimed DNA 284057-91-6
(unclaimed nucleotide sequence; serine proteinase inhibitors and
anticoagulant proteins from Ancylostoma caninum)

L6 ANSWER 8 OF 15 USPATFULL on STN

AN 2000:1845 USPATFULL

TI Circularly permuted ligands and circularly permuted chimeric molecules

IN Pastan, Ira, Potomac, MD, United States

Kreitman, Robert J., Potomac, MD, United States

Puri, Raj K., North Potomac, MD, United States

PA The United States of America as represented by the Department of Health
and Human Services, Washington, DC, United States (U.S. government)

PI US 6011002 20000104

WO 9527732 19951019

<--

AI US 1997-722258 19970108 (8)

WO 1995-US4468 19950406

19970108 PCT 371 date

19970108 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1994-225224, filed on 8 Apr 1994,
now patented, Pat. No. US 5635599

DT Utility

FS Granted

LN.CNT 3244

INCL INCLM: 514/002.000

INCLS: 514/012.000; 530/350.000; 530/351.000; 530/395.000; 530/397.000;
530/399.000; 436/501.000

NCL NCLM: 514/002.000

NCLS: 436/501.000; 514/012.000; 530/350.000; 530/351.000; 530/395.000;

530/397.000; 530/399.000

IC [6]
 ICM C07K014-00
 ICS A61K038-16
 IPCI C07K0014-00 [ICM,6]; A61K0038-16 [ICS,6]
 IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0047-48 [I,C*];
 A61K0047-48 [I,A]; C07K0001-00 [I,C*]; C07K0001-107 [I,A];
 C07K0014-435 [I,C*]; C07K0014-535 [I,A]; C07K0014-54 [I,A];
 C07K0014-55 [I,A]; C07K0016-18 [I,C*]; C07K0016-30 [I,A];
 C12N0015-62 [I,C*]; C12N0015-62 [I,A]

EXF 514/2; 514/8; 514/12; 435/69.1; 435/69.5; 435/69.52; 435/69.7;
 435/172.3; 436/501; 530/350; 530/351; 530/395; 530/397; 530/399

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 6011002 20000104
 WO 9527732 19951019 <--

CC 1-6 (Pharmacology)
 Section cross-reference(s): 3, 15, 34, 63

IT 153272-94-7 157516-02-4 157516-03-5 157516-05-7 253756-32-0, 2:
 PN: US6011002 SEQID: 7 unclaimed DNA 253756-33-1, 3: PN: US6011002
 SEQID: 8 unclaimed DNA 253756-34-2, 4: PN: US6011002 SEQID: 9 unclaimed
 DNA 253756-35-3, 5: PN: US6011002 SEQID: 10 unclaimed DNA
 253756-36-4, 6: PN: US6011002 SEQID: 11 unclaimed DNA 253756-37-5, 8:
 PN: US6011002 SEQID: 13 unclaimed DNA 253756-38-6, 9: PN: US6011002
 SEQID: 14 unclaimed DNA 253756-39-7 253756-40-0 253756-41-1
 253756-42-2 253756-43-3 253756-44-4 253756-45-5 253756-46-6
 253756-47-7 253756-48-8 253756-49-9 253756-50-2
 253756-51-3 253756-52-4 253756-53-5 253756-54-6 253756-55-7
 253756-57-9 253756-60-4 253756-62-6 253756-64-8 253756-68-2
 253756-71-7 253756-75-1 253756-77-3 253756-80-8 253756-82-0
 253756-84-2 253756-85-3 253756-86-4 253756-87-5 253756-88-6
 253756-89-7 253756-90-0 253756-91-1
 (unclaimed nucleotide sequence; circularly permuted ligands and
 circularly permuted chimeric mols. for antitumor therapy)

L6 ANSWER 9 OF 15 USPATFULL on STN

AN 1999:136963 USPATFULL

TI DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide
 receptor (Y4) and uses thereof

IN Bard, Jonathan A., Wyckoff, NJ, United States
 Walker, Mary W., Elmwood Park, NJ, United States
 Branchek, Theresa, Teaneck, NJ, United States
 Weinshank, Richard L., Teaneck, NJ, United States

PA Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S.
 corporation)

PI US 5976814 19991102
 WO 9517906 19950706 <--

AI US 1997-495695 19970113 (8)
 WO 1994-US14436 19941228
 19970113 PCT 371 date
 19970113 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1993-176412, filed on 28 Dec 1993,
 now patented, Pat. No. US 5516653

DT Utility

FS Granted

LN.CNT 3159

INCL INCLM: 435/007.200
 INCLS: 435/069.100; 435/320.100; 435/325.000; 435/252.300; 435/172.300;
 530/350.000; 530/300.000

NCL NCLM: 435/007.200
 NCLS: 435/069.100; 435/252.300; 435/320.100; 435/325.000; 530/300.000;
 530/350.000

IC [6]
 ICM G01N033-53
 ICS C07H021-04; C12N015-12; C12N015-63

IPCI G01N0033-53 [ICM,6]; C07H0021-04 [ICS,6]; C07H0021-00 [ICS,6,C*];
C12N0015-12 [ICS,6]; C12N0015-63 [ICS,6]
IPCR A01K0067-027 [I,C*]; A01K0067-027 [I,A]; A61K0031-70 [I,C*];
A61K0031-70 [I,A]; A61K0035-12 [I,C*]; A61K0035-12 [I,A];
A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61K0039-395 [I,C*];
A61K0039-395 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A];
A61K0048-00 [I,C*]; A61K0048-00 [I,A]; A61P0001-00 [I,C*];
A61P0001-00 [I,A]; A61P0003-00 [I,C*]; A61P0003-04 [I,A];
A61P0009-00 [I,C*]; A61P0009-00 [I,A]; A61P0009-12 [I,A];
A61P0013-00 [I,C*]; A61P0013-02 [I,A]; A61P0015-00 [I,C*];
A61P0015-00 [I,A]; A61P0025-00 [I,C*]; A61P0025-08 [I,A];
A61P0025-20 [I,A]; A61P0025-24 [I,A]; A61P0025-26 [I,A];
A61P0025-28 [I,A]; A61P0033-00 [I,C*]; A61P0033-02 [I,A];
C07H0021-00 [I,C*]; C07H0021-04 [I,A]; C07K0014-435 [I,C*];
C07K0014-705 [I,A]; C12N0005-10 [I,C*]; C12N0005-10 [I,A];
C12N0015-09 [I,C*]; C12N0015-09 [I,A]; C12N0015-12 [I,C*];
C12N0015-12 [I,A]; C12P0021-02 [I,C*]; C12P0021-02 [I,A];
C12P0021-08 [I,C*]; C12P0021-08 [I,A]; C12Q0001-68 [I,C*];
C12Q0001-68 [I,A]

EXF 435/7.2; 435/69.1; 435/320.1; 435/325; 435/252.3; 435/172.3; 530/350;
530/300

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 5976814 19991102

WO 9517906 19950706

<--

CC 2-10 (Mammalian Hormones)

Section cross-reference(s): 1

IT 169108-78-5 181988-77-2, GenBank I20779 181988-78-3, GenBank I20780
181988-79-4, GenBank I20781 181988-80-7, GenBank I20782
181988-81-8, GenBank I20783 181988-82-9, GenBank I20784 181988-83-0,
GenBank I20785 181988-84-1, GenBank I20786 181988-85-2, GenBank
I20787 181988-86-3, GenBank I20788 249559-40-8, PN: US5976814 SEQID:
13 unclaimed DNA 249559-43-1, PN: US5976814 SEQID: 14 unclaimed DNA
249559-46-4, PN: US5976814 SEQID: 15 unclaimed DNA 249559-52-2, PN:
US5976814 SEQID: 16 unclaimed DNA 249559-55-5, PN: US5976814 SEQID: 17
unclaimed DNA 249559-58-8, PN: US5976814 SEQID: 18 unclaimed DNA
249559-60-2, PN: US5976814 SEQID: 19 unclaimed DNA 249559-65-7, PN:
US5976814 SEQID: 20 unclaimed DNA 249559-69-1, PN: US5976814 SEQID: 21
unclaimed DNA 249559-71-5, PN: US5976814 SEQID: 22 unclaimed DNA
249559-75-9, PN: US5976814 SEQID: 23 unclaimed DNA 249559-79-3, PN:
US5976814 SEQID: 24 unclaimed DNA 249559-86-2, PN: US5976814 SEQID: 25
unclaimed DNA 249559-89-5, PN: US5976814 SEQID: 26 unclaimed DNA
249559-93-1, PN: US5976814 SEQID: 27 unclaimed DNA 249560-06-3, PN:
US5976814 SEQID: 29 unclaimed DNA 249560-09-6, PN: US5976814 SEQID: 30
unclaimed DNA 249560-12-1, PN: US5976814 SEQID: 31 unclaimed DNA

(unclaimed nucleotide sequence; method for determining whether chemical
compound

specifically binds to and activates or inhibits activation of human or
rat Y4 receptor)

L6 ANSWER 10 OF 15 USPATFULL on STN

AN 1999:125056 USPATFULL

TI Oligonucleotide N3'→P5' phosphoramidates

IN Gryaznov, Sergei M., San Mateo, CA, United States

Schultz, Ronald G., Urbana, MO, United States

Chen, Jer-kang, Palo Alto, CA, United States

PA Lynx Therapeutics, Inc., Hayward, CA, United States (U.S. corporation)

PI US 5965720 19991012

WO 9525814 19950928

<--

AI US 1997-700448 19970110 (8)

WO 1995-US3575 19950320

19970110 PCT 371 date

19970110 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1994-214599, filed on 18 Mar 1994,
now patented, Pat. No. US 5599922 which is a continuation-in-part of

Set

Ser. No. US 1994-210505, filed on 18 Mar 1994, now abandoned

DT Utility
FS Granted
LN.CNT 2236

INCL INCLM: 536/023.100
INCLS: 435/006.000; 436/501.000; 514/044.000; 536/024.100; 536/024.300;
536/024.310; 536/024.320; 536/024.330; 536/025.300; 935/077.000;
935/078.000

NCL NCLM: 536/023.100
NCLS: 435/006.000; 436/501.000; 536/024.100; 536/024.300; 536/024.310;
536/024.320; 536/024.330; 536/025.300

IC [6]
ICM C12Q001-68
IPCI C12Q0001-68 [ICM,6]
IPCR C12Q0001-02 [I,C*]; C12Q0001-02 [I,A]; A61K0031-70 [I,C*];
A61K0031-70 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7042 [I,A];
A61K0031-7052 [I,A]; A61K0031-7076 [I,A]; A61K0031-708 [I,A];
A61K0031-7088 [I,C*]; A61K0031-7088 [I,A]; A61K0031-7125 [I,C*];
A61K0031-7125 [I,A]; A61K0048-00 [I,C*]; A61K0048-00 [I,A];
A61P0029-00 [I,C*]; A61P0029-00 [I,A]; A61P0031-00 [I,C*];
A61P0031-04 [I,A]; A61P0031-10 [I,A]; A61P0031-12 [I,A];
A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0035-02 [I,A];
A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07H0019-00 [I,C*];
C07H0019-06 [I,A]; C07H0019-16 [I,A]; C07H0019-173 [I,A];
C07H0021-00 [I,C*]; C07H0021-00 [I,A]; C07H0021-04 [I,A];
C12N0015-09 [I,C*]; C12N0015-09 [I,A]; C12Q0001-68 [I,C*];
C12Q0001-68 [I,A]; G01N0033-50 [I,C*]; G01N0033-50 [I,A];
G01N0033-566 [I,C*]; G01N0033-566 [I,A]

EXF 435/6; 436/501; 536/23.1; 536/24.1; 536/24.3-24.33; 536/25.3; 514/44;
935/77; 935/78

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 5965720 19991012
WO 9525814 19950928 <--

CC 33-9 (Carbohydrates)
Section cross-reference(s): 1

IT 60593-72-8P 60593-73-9P 110616-00-7P 111853-81-7P 158913-77-0P
158913-78-1P 158913-79-2P 158913-80-5P 158913-81-6P 158913-82-7P
158913-83-8P 158913-84-9P 158967-24-9P 158967-25-0P 171658-56-3P
171658-57-4P 171658-58-5P 173403-65-1P 173403-66-2P
173403-74-2P 173403-75-3P 173403-78-6P 245354-33-0P 245354-36-3P
245354-38-5P 247036-89-1P 247036-91-5P 247036-94-8P 247037-02-1P
(solid phase synthesis of oligonucleotide N3'→P5' phosphormidate
duplexes and triplexes as antitumor agents)

L6 ANSWER 11 OF 15 USPATFULL on STN

AN 1998:115548 USPATFULL

TI Methods and kits for eukaryotic gene profiling

IN Farr, Spencer B., Longmont, CO, United States
Todd, Marque D., Westminster, CO, United States

PA Pres. and Fellows of Harvard College, Cambridge, MA, United States (U.S.
corporation)
Xenometrix, Inc., United States (U.S. corporation)

PI US 5811231 19980922
WO 9417208 19940804 <--

AI US 1995-374641 19950721 (8)
WO 1994-US583 19940121
19950721 PCT 371 date
19950721 PCT 102(e) date

RLI Continuation of Ser. No. US 1993-8896, filed on 21 Jan 1993, now
abandoned

DT Utility
FS Granted
LN.CNT 2382

INCL INCLM: 435/006.000

Duffy, Patricia

From: Duffy, Patricia
Sent: Thursday, March 01, 2007 3:22 PM
To: STIC-ILL
Subject: copies of references please ASAP 09/770,943

Fujihasi (ACTA ODONTOL Scand 2001, 59:301-308).

Jiang et al (Br. J. Ophtamol, 2001 85:739-44)

Zivny et al (Clin Immunology 2001, 101:150-68).

Patricia A. Duffy, Ph.D.
Primary Patent Examiner
571-272-0855,
Remsen 3B05,
Mailbox: 3C18

? ds

Set	Items	Description
S1	7604	AUTOIMMUNE DISEASE AND DT=REVIEW
S2	332	S1 AND PY<1998
S3	309	RD S2 (unique items)
S4	273	S3 AND PY>1994
S5	288670	S4 AND MYELIN OR LUPUS OR SJORGENS
S6	67	S4 AND (MYELIN OR LUPUS OR SJORGEN'S)
S7	67	RD S6 (unique items)
?		